xenograft model was used to assess the effects of miR-144-3p overexpression on tumorigenesis. Bioinformatics analysis and dualluciferase reporter assay were used to indentify AT-rich interactive domain 1A (ARID1A) as a direct target gene of miR-144-3p. Quantitative RT-PCR, Western blotting, and immunohistochemical (IHC) staining were used to explore ARID1A expression level of the mRNA and protein RESULTS: We found that miR-144-3p was the only upregulated miRNA both in clear cell renal cell carcinoma (ccRCC) tissue samples matched with normal kidney tissues and in paired preoperative matched with postoperative plasmas and miR-144-3p overexpression enhanced cell proliferation, clonogenicity, migration, invasion, and chemoresistance in ccRCC cells. Notably, the oncotumor activities of miR-144-3p were mediated by repressing the expression of ARID1A. The downregulation of ARIDIA could promote the function of miR-144-3p in cell proliferation, metastasis and chemoresistance. Consistently, ARID1A mRNA and protein levels were decreased in ccRCC and in nude mice, and they negatively correlated with miR-144-3p CONCLUSIONS: Higher miR-144-3p may enhance malignancy and resistance to Sunitinib in ccRCC by targeting ARID1A, the observations may uncover novel strategies of ccRCC treatment.
INTRODUCTION AND OBJECTIVES:
The estrogen receptor beta (ERb), first discovered in 1996, has been recognized as a protective nuclear receptor in many hormone-sensitive tumors, including breast and prostate cancers. Yet in contrast, ERb can also promote progression of bladder cancer. The roles of ERb in RCC, however, remain to be further elucidated. Here we found ERb could promote the RCC progression, and clinical sample investigation revealed that a higher ERb expression is correlated with a worse overall survival rate/a shorter disease-free survival in RCC patients. The identification of the ERb-HOTAIR-ceRNA axis may provide us new biomarkers and/or therapeutic targets to better suppress RCC progression in the future.
METHODS: RNAseq Data (TCGA, provisional of 537 RCC patients) were retrieved from the TCGA database. The role of ERb, and the relationship between ERb and HOTAIR were investigated thoroughly through in vitro and in vivo experiments. We established the orthotopic RCC model by implanting luciferase-labeled 786-O/Scr or 786-O/shERb cells, also transduced into 6-week-old female nude mice (n ¼ 8 mice per group). The non-invasive in vivo imaging system (IVIS) was used every 2 weeks to monitor tumor progression.
RESULTS: Here, we provide clinical evidence that ERb expression is correlated in a negative manner with the overall survival/ disease-free survival in RCC patients. Mechanism dissection revealed that targeting ERb with ERb-shRNA and stimulating the transactivation of ERb with 17b-estradiol or environmental endocrine disrupting chemicals, all resulted in altering the lncRNA HOTAIR expression. The ERb-modulated HOTAIR is able to function via antagonizing several microRNAs, including miR-138, -200c, -204, or -217 to impact various oncogenes, including ADAM9, CCND2, EZH2, VEGFA, VIM, ZEB1, and ZEB2, to promote RCC proliferation and invasion.
CONCLUSIONS: Our new finding from multiple RCC cell lines and the preclinical mouse RCC model as well as TCGA database analysis all conclude that ERb could play a key role to promote ccRCC progression. This study focused on mechanisms how ERb could promote RCC progression though transcriptionally up-regulating lncRNA HOTAIR and shifting the entire associated ceRNA and oncogene network. If supporting evidence continues to emerge, ERb may become a feasible therapy target for metastatic RCC treatment and emerge as one important biomarker for the prediction of overall survival and progression-free survival. METHODS: We detected miR-124 and MEG3 expression by quantitative real-time polymerase chain reaction. Oligonucleotides were used to over express miR-124. Cell proliferation, invasion and migration were done to examine effects on cancer cell proliferation. Luciferase assay was performed to verify the precise target of miR-124.
RESULTS: Here we found that miR-124 and MEG3 were both strongly reduced in RCC, and combined expression of miR-124 and MEG3 emerged as an independent prognostic factor in RCC patients. Overexpression of miR-124 or MEG3 in ACHN and 786-O cells inhibited cell proliferation, suppressed cell invasion and metastasis. Using DZNep and siRNA to knockdown EZH2, we found EZH2 induced the epigenetic silencing of miR-124 and MEG3 expression by H3K27me3. Assays in RCC ACHN and 786-O cells showed that miR-124 directly targeted the TET1 transcript and that its inhibition could result in the upregulation of MEG3. RIP assay indicated that MEG3 induced p53 protein accumulation, while ChIP assay demonstrated p53 was a positive transcriptional regulator of the miR-124 by promoter activation. These three crosstalks of interaction between miR-124 and MEG3 providing a plausible link for the two most downregulated and positive correlated non-coding RNAs. Finally, we proved that PTPN11 were the direct targets of miR-124 as well as the MEG3 and p53 regulated genes, through which mediating the tumor Vol. 199, No. 4S, Supplement, Monday, May 21, 2018 THE JOURNAL OF UROLOGY â e1201
